Whalesbook
Take Solutions has made a rapid comeback, transforming from a company facing near bankruptcy to a strong performer. The firm tackled significant debt challenges, which had peaked at ₹2,400 crore in March 2020. By divesting key subsidiaries, including Navitas Life Sciences and Acunova entities to HIG Capital affiliates, and focusing on integrating AI into clinical research and life sciences, the company has dramatically improved its financial standing.
Debt Slashed, AI Drives New Growth
This restructuring has drastically reduced the company's debt to ₹35 crore as of September 2025, a significant improvement from its past financial difficulties. The shift to AI-driven healthcare and consumer wellness solutions has strengthened its balance sheet and opened doors for new growth opportunities. Ecron Acunova now stands as its main operational asset, signaling the start of a new phase.
New Frontier: Take Solutions Targets Anti-Aging Boom
The company's newest strategy focuses on the fast-growing anti-aging and longevity market. Take Solutions plans to develop science-backed nutraceuticals, biohacking tools, and tech-enabled preventive healthcare products. Management sees this as a logical step, building on their existing expertise in clinical research, life sciences, and regulatory compliance. The potential market is substantial, with India's preventive healthcare sector alone valued at about $197 billion and global markets showing strong growth.
Challenges Ahead for New Ventures
While the pivot is ambitious and market conditions are favorable due to increased health awareness and lifestyle diseases, the anti-aging venture is still in its early stages. Current financial reports show zero profit and loss for this new segment, meaning no revenue has been generated yet. The next few months will be crucial to see if Take Solutions can secure partnerships, launch products, and execute its strategy successfully to capture opportunities in this developing market.